[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 601
Citations 0
In This Issue of JAMA
October 18, 2016

Highlights

JAMA. 2016;316(15):1515-1517. doi:10.1001/jama.2015.14536

Empirical antifungal therapy is often used in the treatment of intensive care unit (ICU)–acquired sepsis—despite a lack of evidence that the practice improves outcomes. In a multicenter placebo-controlled randomized clinical trial involving 260 critically ill adults with unresolved sepsis (despite treatment with broad-spectrum antibiotics), Candida colonization at multiple sites, and multiple organ failure, Timsit and colleagues found that 14 days’ treatment with micafungin did not increase fungal infection–free survival at day 28. In an Editorial, Siddharthan and colleagues discuss empirical vs targeted treatment of invasive fungal infections.

First Page Preview View Large
First page PDF preview
First page PDF preview
×